Neuroscience Honor Society Induction Will Be March 31 – University of St. Thomas Newsroom

The sixth annual Distinguished Lecture in Neuroscience and Nu Rho Psi honorary society induction will be held Friday, March 31, at 3 p.m. in John Roach Center, Room 126. The neuroscience program will induct 15 new members into Nu Rho Psi, the neuroscience national honor society.

The new members who will be inducted in Nu Rho Psi are: Kaycie Anderson, Katelyn Baier, Elizabeth Baker, Joana Beyer, Brooke Finch, Salman Irfanullah, Katherine Leininger, Tyler Lifke, Kha Lor, Elliot Magnuson, Zachari Mertes, Catherine Minz, Hannah Moyer, Molly Richardson and Georgianna Younger.

Following the program, Dr. Keith B. Hengen will deliver the Distinguished Lecture in Neuroscience. Hengen, an assistant professor of biology at Washington University in St. Louis, uses computation approaches to explore the homeostatic self-organization of intact neural networks that support sensation, perception and cognition, and how appropriate information transmission in these systems is established during development and disrupted in disease. His lecture, Keeping it together at every level: Self-organization of neurons and networks will discuss the role of sleep wake in chaperoning the interactions between distinct plasticity mechanisms.

Read this article:
Neuroscience Honor Society Induction Will Be March 31 - University of St. Thomas Newsroom

Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR … – Yahoo Finance

STRASBOURG, France--(BUSINESS WIRE)--

Regulatory News:

Transgene (TNG.PA), a biotechnology company focused on designing and developing viral-based immune-targeted therapies for the treatment of cancers and infectious diseases, announces today that it will present a poster with new and encouraging preclinical data of a next generation armed engineered oncolytic virus at the American Association for Cancer Research annual meeting in Washington, DC.

This immunological data further support the development of armed oncolytic viruses that have the capacity to modulate the tumor micro-environment and improve T-cell infiltration in the tumor.

Key highlights:

The poster entitled Local and abscopal effects in oncolytic virotherapy are boosted by immune checkpoint blockade, immunogenic chemotherapy, or IFNAR blockade will be presented on Tuesday, April 4th, from 1:00 to 5:00pm EST in the section25. The abstract is available on the AACR website.

The poster presents preclinical results of a modified vaccinia virus expressing the Fcu1 gene (VVWR-TK-RR--Fcu1), which is able to transform the non-cytotoxic pro-drug, flucytosine (5-FC), into 5-FU, a widely used cancer chemotherapy. Results show that this next generation armed oncolytic virus is able to induce an immunogenic cell death and thus to generate a systemic immune response in immuno-competent mouse models.

These preclinical data further strengthen the preclinical data package of Transgenes most advanced next generation oncolytic virus, TG6002. TG6002 is due to enter the clinic in H12017 in patients with recurrent glioblastoma.

About Transgene Transgene S.A. (TNG.PA), part of Institut Mrieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgenes programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Companystwo lead clinical-stage programs are: TG4010, a therapeutic vaccine for non-small cell lung cancer and Pexa-Vec, an oncolytic virus for liver cancer. The Company has several other programs in clinical and preclinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at http://www.transgene.fr.

Follow us on Twitter: @TransgeneSA

Disclaimer This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Companys activities, perspectives, financial situation, results, regulatory authorities agreement with development phases, and development. The Companys ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Companys actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (Facteurs de Risque) section of the Document de Rfrence, available on the AMF website (http://www.amf-france.org) or on Transgenes website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170330005720/en/

More here:
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR ... - Yahoo Finance

Immune Deficiency Foundation Continues Partnership with Clinical Immunology Society to Promote – PR Newswire (press release)

As organizations that work closely with the PI community, IDF and CIS want to educate the public about PI during Awareness Month and World PI Week. Although some types present at birth or in early childhood, the disorders can affect anyone, regardless of age or gender. They are caused by hereditary or genetic defects and are not contagious.

Theme of World PI Week Focuses on Access to Ig Therapy Leading up to and throughout World PI Week, IDF and CIS will lead the PI community in raising awareness and improving access to lifesaving immunoglobulin replacement (Ig) therapy for people with these rare, chronic conditions. Ig replacement therapy, which is derived from human plasma, provides antibodies to protect against a broad range of infections, and it is life sustaining and lifelong for many with PI. Such treatments exist for people with PI, but access to them can vary significantly across continents and countries of a same region. The World PI Week aims to help drive change and equal access to quality treatment for all patients.

CIS Annual Meeting Kicked off Awareness Month During the CIS Annual Meeting, held March 23-26, 2017 in Seattle, members of CIS presented new research findings and discussed treatments for PI with more than 600 meeting attendees. Serving as a kick-off for Awareness Month and World PI Week, IDF staff members also participated and shared the Foundation's resources for the PI community. The organizations will also mail IDF educational materials to all CIS members.

"The Clinical Immunology Society promotes excellence in the care of patients with immunologic/inflammatory disorders, including primary immunodeficiency diseases. It is essential that patients receive proper treatment under the care of a specialist," Roshini Sarah Abraham, PhD, CIS President. "We are proud to partner with IDF during Awareness Month and World PI Week to help increase awareness of these complex diseases and to ensure access to lifesaving treatments."

With early diagnosis and proper medical care, many people with PI can live long, healthy lives. For more information, visit http://www.primaryimmune.org or call 800-296-4433.

World PI Week: April 22-29 IDF and CIS are joining organizations across the globe to promote awareness of primary immunodeficiency diseases during World PI Week, April 22-29. IDF participates in international initiatives with the objective to Test, Diagnose and Treat! For more information about World PI Week, visit http://www.worldpiweek.org.

About the Immune Deficiency Foundation The Immune Deficiency Foundation (IDF), founded in 1980, is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases (PI) through advocacy, education and research. IDF provides accurate and timely information for individuals and families living with PI and offers valuable resources. To learn more about IDF, visit http://www.primaryimmune.org.

About the Clinical Immunology Society The Clinical Immunology Society (CIS), established in 1986, is devoted to fostering developments in the science and practice of clinical immunology. CIS works to facilitate education, translational research and novel approaches to therapy in clinical immunology to promote excellence in the care of patients with immunologic/inflammatory disorders. To learn more about CIS, visit http://www.clinimmsoc.org.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immune-deficiency-foundation-continues-partnership-with-clinical-immunology-society-to-promote-national-primary-immunodeficiency-awareness-month-and-world-pi-week-in-april-300432237.html

SOURCE Immune Deficiency Foundation

http://www.primaryimmune.org

Follow this link:
Immune Deficiency Foundation Continues Partnership with Clinical Immunology Society to Promote - PR Newswire (press release)

Following industry trend, Merck offloads mid-stage immunology candidate – The Pharma Letter (registration)

Merck KGaA and London-based Avillion have signed an agreement to collaborate on the development of the

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

Avillion LLPBiotechnologyDealsGermanyImmunologicalsLicensingMerck KGaAUK

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

Here is the original post:
Following industry trend, Merck offloads mid-stage immunology candidate - The Pharma Letter (registration)

Drastic cuts to NIH budget could translate to less innovation and fewer patents, study argues – Los Angeles Times

From research on stem cells and DNA sequencing to experiments with fruit flies and surveys of human behavior, projects funded by the National Institutes of Health aim to make Americans healthier. A new analysis finds that NIH-funded research also fuels the kinds of innovations that drive the U.S. economy.

Between 1990 and 2012, close to 1 in 10 projects made possible by an NIH grant resulted in a patent, usually for a university or a hospital.

The indirect effects were far greater: Close to 1 in 3 NIH research grants generated work that was cited in applications for commercial patents.

Over roughly two decades, 81,462 patents filed by companies and individuals cited at least one NIH-sponsored research project in their applications. Some 1,351 of those patents were for drugs that would go on to be approved by the Food and Drug Administration.

The study, published Thursday in the journal Science, undergirds a point repeated frequently since the Trump administration unveiled a budget plan that proposed cutting the NIH budget by 20% in 2018: that research funded by taxpayer dollars not only improves lives and forestalls death, it creates jobs which the president has long asserted is his highest priority.

It is an argument often made in support of such scientific undertakings as space exploration, and sometimes for defense spending. But when it comes to biomedical research, public spending is frequently dismissed as a way to sustain university professors or seek esoteric answers to the mysteries of life.

It shouldnt be, said Pierre Azoulay, a professor of technological innovation at MIT and coauthor of the new analysis.

NIH public funding expenditures have large effects on the patenting output of the private sector, Azoulay said. These results should give a lot of pause to those who think these cuts are going to have no effect.

Ashley J. Stevens, a biotechnology researcher who is president of Focus IP Group in Winchester, Mass., said the new study clearly ... supports the premise that increased investment in the NIH leads directly to improved public health.

It also makes President Trumps proposal to cut the NIH budget by $1.6 billion this year and $6 billion next year to fund a border wall and increased military spending incompatible with his America first objectives, added Stevens, who was not involved in the study.

More than 80% of the NIH budget is parceled out to researchers across the country and around the world. Each year, NIHs 21 institutes award close to 50,000 competitive grants to investigators at more than 2,500 universities, independent labs and private companies. The University of California, for instance, received nearly $1.9 billion in total NIH funding last year.

Led by Harvard Business School entrepreneurship professor Danielle Li, the new research scoured 1,310,700 patent applications submitted between 1980 and 2012 in the life sciences, a category that includes drugs, medical devices and related technologies. In the footnotes, citations and supporting data, the study authors looked for references to any of the 365,380 grants the NIH funded between 1980 and 2007, as well as to research articles generated by those grants.

To capture the unappreciated indirect spillovers of knowledge that result from NIH-funded work, the authors focused especially on 232,276 private-sector patents in the life sciences.

Li, Azoulay and Bhaven Sampat, a health policy professor at Columbia University, found 17,093 patents that were assigned to universities and public-sector institutions. These patents are certainly valuable they can spur further research, support professors and graduate students and boost endowments.

But private-sector patents may reverberate more widely through the economy, generating capital, manufacturing jobs and profits. And their intellectual debt to publicly funded research is rarely counted or acknowledged outside the fine print of these patent applications.

In all, 112,408 NIH-funded research grants 31% of the total disbursed between 1990 and 2007 produced research that was cited by 81,462 private-sector patents, the team found.

If you thought this was just ivory tower stuff that has no relevance, I think we contradict that, Azoulay said.

The findings demonstrate that the broad economic effects of NIH budget cuts would not necessarily be felt immediately, since it could take years for a research paper written by NIH-funded investigators to find its way into a patent application.

These effects are going to be delayed, Azoulay said. The slowdown resulting from a cut in the NIH budget now is for President Ivanka Trump or President Chelsea Clinton to worry about.

But the study also makes clear that publicly funded research lays the groundwork for important innovations and discoveries that companies and individuals seek to patent.

Biomedical research is perhaps the most complex type of research there is, Azoulay added: These are fundamentally harder problems. There are a lot of blind alleys, experimentation that leads to nothing.

Intriguingly, the new research found that there was little difference in the economic impact of grants for basic science and applied science. Both types of grants were equally likely to be cited in patent applications if they explored fundamental dynamics of biology (such as cellular processes) or if they studied specific disease states in humans.

That distinction is important, because researchers and scientific leaders have quarreled for years over how NIHs limited budgets should be apportioned.

Scientists who study very basic biological processes, or who work with simple organisms like yeast, earthworms or fruit flies, often argue that their contributions are most valuable because they shed light on how all life including human life works.

Scientists whose research is more applied, including clinical trials and epidemiological studies, believe their work contributes more directly to improving human health.

The new study suggests that both categories contribute to commercial innovation.

Stevens called this finding remarkable.

Azoulay acknowledged that neither the progress of life sciences research nor its contribution to the economy is neat or easy to quantify.

See more here:
Drastic cuts to NIH budget could translate to less innovation and fewer patents, study argues - Los Angeles Times

The road to recovery means taking care of species besides just humans – The Altamont Enterprise

We had been worrying about frogs frogs that went to vernal pools to mate that then got covered with snow.

In late February, when the weather was unseasonably warm, we had gotten a press release from the states Department of Environmental Conservation that usually comes in late March. We look forward to receiving it every year. For us, it epitomizes human beings trying to make amends to the natural world we have tampered with.

After the ground has thawed, wood frogs and spotted salamanders, among other species, come out from their underground winter shelters in the woods to get to pools to breed. In the past, weve covered big-night migrations where the roads seemed to undulate with the massive movement of amphibians.

Volunteers with the DECs Amphibian Migrations and Road Crossings Project not only record the weather conditions and count the amphibians, they help them safely cross the road, cautioning drivers and routing traffic around the well-traveled routes. The project is in its ninth year and so far 300 volunteers have helped more than 8,500 amphibians cross the road.

Earlier this month, after two feet of snow had fallen, we were interviewing Alvin Breisch about his new book, The Snake and the Salamander. For 26 years, until his retirement in 2009, Breisch was New York States amphibian and reptile specialist. He studied, catalogued, and worked to preserve the states herpetofauna its amphibians and reptiles, known as herps.

Who better to ask about our worries? We wondered if the frogs we had seen crossing our road to the pool on the other side that warm February night would be nipped in the bud like the cherry blossoms had been in Washington, D.C. this year.

Breisch told us, no it was the male frogs who had crossed to the pool and they would wait for the females.

Even with the snow? we asked.

Even with the snow, he said.

We spoke with Breisch about a wide variety of projects he has been involved with over the years to save species that otherwise would through human behavior become extinct.

Breisch was with the Endangered Species Unit and decided to use the same thought process for endangered reptiles and amphibians as the department used with game animals, setting bag limits.

For example, there were no regulations for the diamond-backed terrapin on Long Island, the only turtle that lives in brackish water. They were considered good eating; there were no regulations, recalled Breisch. He said that 10,000 to 20,000 were sold each year in New York Citys Fulton Fish Market.

We drafted regulations to limit harvest to have a self-sustaining population, said Breisch. It worked for years.

Currently, Breisch is working with a group of scientists on a Timber Rattlesnake Conservation Action Plan, documenting the current and historic range of the snake from Quebec to Texas and Florida and as far west as Minnesota. The area covers two Canadian provinces and 30-odd states. Breisch is a co-author for the New York State portion and editor for the entire work.

We saw inconsistent ways states were managing the snakes, he said of the reason for undertaking the project. He gave an example that he termed indescribably awful: Texas has rattlesnake roundups, so-called celebrations, where people collect live snakes, and use them for side-show type things, like hand-milking snakes or holding bagging contests.

This involves contestants entering a pit full of snakes and throwing them into bags. Its not good for the snakes and its not good for the people, he said. People get bitten and die. Most of the snakes die.

There are no timber rattlesnakes left in Canada, Breisch said, and Ontario is looking to see if the snakes might be reintroduced.

We asked why anyone would want to re-introduce a venomous snake, and Breisch replied, Its a movement among virtually all naturalists wed like to see a complete suite of different animals...Were looking for high biodiversity.

He went on, The health of the environment is better if you have a significant number of native species. Returning to the timber rattlesnake, as an example, he explained that they eat small rodents. Rodents do crop damage and tree damage; they carry black-legged ticks that carry Lyme disease.

Breisch had suffered, as had we, from another tick-borne disease, one that can be fatal, anaplasmosis, so that connection hit home.

During a podcast, Breisch gave us another example of an animal considered harmful being reintroduced into its native habitat: The wolf, absent for decades, was reintroduced into Yellowstone National Park. The thought was that wolves would help keep the overpopulation of deer, moose, and elk in check.

Follow-up studies showed that had happened as expected, Breisch said, but there was an unexpected impact on vegetation. The banks had been de-vegetated by the elk. With the wolves keeping the elk population under natural control, the streams became healthy again, he said

Humans have great hubris. The wilderness that our pioneer ancestors tamed now has to be re-invented and protected.

Each species is unique, said Breisch. We havent gotten to the point we understand that uniqueness.

He gave a practical example of the Massasauga rattlesnake from which a vaccination was developed in the 1800s, used as a model for vaccinations for other diseases.

But beyond the direct benefit of certain species to humans and our livestock, there are connections in the natural world that we have destroyed or are destroying that we dont understand.

Sure, we were relieved to learn that the male frogs are waiting patiently beneath the snow for their female mates to arrive. But we went on to reflect how odd it was that we should worry about a few frogs we had blithely seen hopping across our road that warm February night but not the enormity of all we as human beings had done to disturb the natural order weve stayed warm these cold spring nights in our home heated with oil. Each day we drive to work in our car fueled with gasoline.

We know these fossil fuels are destroying our planet and may even be causing the erratic weather we are right now experiencing, and yet we go on, taking the path most familiar to us.

In the same way we trusted Al Breisch, as a qualified scientist, to quell our fears about the frogs, we trust the vast majority of scientists who have studied climate change and determined that humans are affecting it.

Were grateful we live in New York State that is moving forward with, even as the federal government is starting to peel back, programs that promote renewable energy.

While we commend the citizens who stand in the rain to help the amphibians cross the road, we urge still greater commitment to reduce the human footprint upon our Earth.

Melissa Hale-Spencer

Here is the original post:
The road to recovery means taking care of species besides just humans - The Altamont Enterprise

Stem cells help explain varied genetics behind rare neurologic disease – Medical Xpress

March 30, 2017

Researchers at Case Western Reserve University School of Medicine have successfully grown stem cells from children with a devastating neurological disease to help explain how different genetic backgrounds can cause common symptoms. The work sheds light on how certain brain disorders develop, and provides a framework for developing and testing new therapeutics. Medications that appear promising when exposed to the new cells could be precisely tailored to individual patients based on their genetic background.

In the new study, published in The American Journal of Human Genetics, researchers used stem cells in their laboratory to simultaneously model different genetic scenarios that underlie neurologic disease. They identified individual and shared defects in the cells that could inform treatment efforts.

The researchers developed programmable stem cells, called induced pluripotent stem cells, from 12 children with various forms of Pelizaeus-Merzbacher Disease, or PMD. The rare but often fatal genetic disease can be caused by one of hundreds of mutations in a gene critical to the proper production of nerve cell insulation, or myelin. Some children with PMD have missing, partial, duplicate, or even triplicate copies of this gene, while others have only a small mutation. With so many potential causes, researchers have been in desperate need of a way to accurately and efficiently model genetic diseases like PMD in human cells.

By recapitulating multiple stages of the disease in their laboratory, the researchers established a broad platform for testing new therapeutics at the molecular and cellular level. They were also able to link defects in brain cell function to patient genetics.

"Stem cell technology allowed us to grow cells that make myelin in the laboratory directly from individual PMD patients. By studying a wide spectrum of patients, we found that there are distinct patient subgroups.

This suggests that individual PMD patients may require different clinical treatment approaches," said Paul Tesar, PhD, study lead, Dr. Donald and Ruth Weber Goodman Professor of Innovative Therapeutics, and Associate Professor of Genetics and Genome Sciences at Case Western Reserve University School of Medicine.

The researchers watched in real-time as the patients' stem cells matured in the laboratory. "We leveraged the ability to access patient-specific brain cells to understand why these cells are dysfunctional. We found that a subset of patients exhibited an overt dysfunction in certain cellular stress pathways," said Zachary Nevin, first author of the study and MD/PhD student at Case Western Reserve University School of Medicine. "We used the cells to create a screening platform that can test medications for the ability to restore cell function and myelin. Encouragingly, we identified molecules that could reverse some of the deficits." The promising finding provides proof-of-concept that medications that mend a patient's cells in the laboratory could be advanced to clinical testing in the future.

The stem cell platform could also help other researchers study and classify genetic diseases with varied causes, particularly other neurologic disorders. Said Tesar, "Neurological conditions present a unique challenge, since the disease-causing cells are locked away in patients' brains and inaccessible to study. With these new patient-derived stem cells, we can now model disease symptoms in the laboratory and begin to understand ways to reverse them."

Explore further: Researchers turn urine into research tools

Each face is unique, even though the genes controlling facial shape are almost identical in every individual. Filippo Rijli and his team at the Friedrich Miescher Institute for Biomedical Research (FMI) have discovered an ...

Researchers at Case Western Reserve University School of Medicine have successfully grown stem cells from children with a devastating neurological disease to help explain how different genetic backgrounds can cause common ...

By inserting an amyotrophic lateral sclerosis (ALS)-linked human gene called TDP-43 into fruit flies, researchers at Stony Brook University and Cold Spring Harbor Laboratory discovered a potential role for 'transposons' in ...

A genetic trawl through the DNA of almost 100,000 people, including 17,000 patients with the most common type of ovarian cancer, has identified 12 new genetic variants that increase risk of developing the disease and confirmed ...

In a research effort that merged genetics, physics and information theory, a team at the schools of medicine and engineering at The Johns Hopkins University has added significantly to evidence that large regions of the human ...

An international consortium of researchers led by Dr. Melissa Bondy, professor of medicine, associate director for population sciences at the Dan L Duncan Comprehensive Cancer Center and McNair Scholar at Baylor College of ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Link:
Stem cells help explain varied genetics behind rare neurologic disease - Medical Xpress

Celina seed industry veterans launch new company, B&A Genetics – Lima Ohio

In this photo taken Nov. 2009, central Illinois corn farmers harvest their crops near Waverly, Ill. While a Senate vote to end a tax credit that's helped build the ethanol industry in the United States signals that the subsidy's days may be numbered, corn farmers and ethanol makers hope they can convince Congress to compromise and agree to preserve but reduce subsidies. But agricultural economists say the ethanol industry has grown up over the last few years and doesn't need the help, and they doubt farmers or their customers in the ethanol industry would be hurt much if the subsidy dies. (AP Photo/Seth Perlman)

CELINA Two seed industry experts, Max Bixler and Gregg Adams, have launched a new company, B&A Genetics. The company will serve farmers in Indiana, Ohio and Illinois, and offers a diverse portfolio of the newest, elite germplasm, as well as a customized, one-on-one approach to help farmers simplify their operations and increase crop yields.

Bixler and Adams have more than 15 years of experience in the seed industry.

For more information about B&A Genetics, call 419-305-5481 or visit http://bagenetics.us.

In this photo taken Nov. 2009, central Illinois corn farmers harvest their crops near Waverly, Ill. While a Senate vote to end a tax credit that's helped build the ethanol industry in the United States signals that the subsidy's days may be numbered, corn farmers and ethanol makers hope they can convince Congress to compromise and agree to preserve but reduce subsidies. But agricultural economists say the ethanol industry has grown up over the last few years and doesn't need the help, and they doubt farmers or their customers in the ethanol industry would be hurt much if the subsidy dies. (AP Photo/Seth Perlman)

http://limaohio.com/wp-content/uploads/2017/03/web1_Harvest.jpgIn this photo taken Nov. 2009, central Illinois corn farmers harvest their crops near Waverly, Ill. While a Senate vote to end a tax credit that's helped build the ethanol industry in the United States signals that the subsidy's days may be numbered, corn farmers and ethanol makers hope they can convince Congress to compromise and agree to preserve but reduce subsidies. But agricultural economists say the ethanol industry has grown up over the last few years and doesn't need the help, and they doubt farmers or their customers in the ethanol industry would be hurt much if the subsidy dies. (AP Photo/Seth Perlman)

.

Here is the original post:
Celina seed industry veterans launch new company, B&A Genetics - Lima Ohio

Lab report – Prospect

Lisa Jardine is the right woman for the HFEA. Pfizer fails to rewrite the rules of science. And sentimentality has deprived Nasa of a highly capable head of science by Philip Ball / May 24, 2008 / Leave a comment Published in May 2008 issue of Prospect Magazine

Can Lisa Jardine save embryology?

Historian Lisa Jardine, the new head of the Human Fertilisation and Embryology Authority (HFEA), begins her role ahead of the impending Commons vote on the human fertilisation and embryology bill. The bill crystallises several moral dilemmas about research and practice in these areas, and threatens to intensify the polarisation they induce. Whatever position Jardine takes is sure to upset some vocal group or other.

This is why the appointment of someone used to taking the long view, and accustomed to the hard knocks of public life, probably makes sense. Certainly, Jardines popularising instincts seem right for the HFEA just now: she considers public education about fertility issues as important as the regulatory responsibilities. The HFEA has hitherto seldom shown an explicit commitment to inform.

So far, the misinformation about the bill spread by Catholic officials and other religious groupstalk of animal-human cybrid embryos in research as of Frankenstein proportiondoes not seem to have dented public appreciation of the potential benefits of such research. (The animal component would be a mere shell for human genes.) But it is never a good idea to underestimate the determination of zealots.

It is great to see that you are enjoying the Prospect website.

You have now reached your allowance of 3 free articles in the last 30 days. Dont worryto get another 7 articles absolutely free, just enter your email address in the box below.

You are in complete control of which 7 articles you choose to read. Register now to enjoy more of the finest writing on politics, economics, literature, the arts, philosophy and science.

When you register, well also send you our free e-bookThe past in perspectivewhich considers how reflecting on the past can give great insight into the present AND well send you our free weekly newsletter. (If you prefer not to receive the newsletter you can unsubscribe at any time).

Prospect takes your privacy seriously. We promise never to rent or sell your e-mail address to any third party. You can unsubscribe from the Prospect e-mail newsletter at any time.

Excerpt from:
Lab report - Prospect

Online Medical Biochemistry: Online Biochemistry Course

Contact Us: (855) 325-0894 | Email our Staff

UNE Academic Calendars| UNE Academic Catalog|Technical Requirements

This is a one-semester online Biochemistry course designed for individuals who need first semester Biochemistry as a prerequisite to apply for admission to a program in the health professions.

Graduate programs that may require a CHEM 1005 Medical Biochemistry class include:

Medical Biochemistry is a four credit hour course designed to lay the foundation for other basic and clinical medical sciences. The goal of this course is to learn the core concepts of biochemistry that apply to human health and disease and to cite specific examples of their application. You will be able to analyze and evaluate the most common biochemistry cited in medical literature. Furthermore, these basics will facilitate further learning in biochemistry and the health sciences.Click here for the online Biochemistry course syllabus.More detailed readings are available on Blackboard.

The typical student will complete this online Biochemistry course in approximately 16 weeks. Many students are nontraditional students who have elected an online course for flexibility. Since the course is self-paced, you may complete the course in fewerthan 16 weeks.

One semester of college level biology, and one year of chemistry that includes one semester of organic chemistry.All prerequisite courses must have been completed successfully within the past seven years.

To learn more about the technical requirements for this and other Post-Baccalaureate courses, click here.

Credits: 4 Tuition: $1320 Registration: $25 Total: $1345

The cost of the materials is not included in this total.

All exams are taken online. Major exams are required to be proctored. For instructions on how to take your exams online, visit Online Learning's ProctorU site.

You may enroll at any time via our self-service registration portal.Please keep in mind that courses start on the 1st and 3rd Wednesdays of the month. Payment is due in full atthe time of registration. Your official start date is the date that the course opens, and you will have 16 weeks from that date to complete your course.

You must be registered for yourclass by 12:00 noon EST on the Mondaybefore the class starts.See the UNEAcademic Calendarfor more details.

If you have any questions or need help with registering for your class, please callan Enrollment Counselorat1-855-325-0894, email prehealth@une.edu, or view the online FlexReg course registration tutorial.

If you intend to useVA Benefits or Military Tuition Assistance, please do not usethe self-registration portal. Please call 1-855-325-0894 to be directed to the appropriate office for assistance.

Register NowRequest Information

Can't find what you are looking for? Suggest a course.

Read more:
Online Medical Biochemistry: Online Biochemistry Course